ATE462003T1 - Aus wt1 stammende krebsantigenpeptide - Google Patents

Aus wt1 stammende krebsantigenpeptide

Info

Publication number
ATE462003T1
ATE462003T1 AT05727848T AT05727848T ATE462003T1 AT E462003 T1 ATE462003 T1 AT E462003T1 AT 05727848 T AT05727848 T AT 05727848T AT 05727848 T AT05727848 T AT 05727848T AT E462003 T1 ATE462003 T1 AT E462003T1
Authority
AT
Austria
Prior art keywords
peptides derived
cancer antigen
antigen peptides
peptide
cancer
Prior art date
Application number
AT05727848T
Other languages
English (en)
Inventor
Haruo Sugiyama
Original Assignee
Int Inst Cancer Immunology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Int Inst Cancer Immunology Inc filed Critical Int Inst Cancer Immunology Inc
Application granted granted Critical
Publication of ATE462003T1 publication Critical patent/ATE462003T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
AT05727848T 2004-03-31 2005-03-30 Aus wt1 stammende krebsantigenpeptide ATE462003T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004105219 2004-03-31
PCT/JP2005/006113 WO2005095598A1 (ja) 2004-03-31 2005-03-30 Ｗｔ１由来の癌抗原ペプチド

Publications (1)

Publication Number Publication Date
ATE462003T1 true ATE462003T1 (de) 2010-04-15

Family

ID=35063778

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05727848T ATE462003T1 (de) 2004-03-31 2005-03-30 Aus wt1 stammende krebsantigenpeptide

Country Status (11)

Country Link
US (3) US7622119B2 (de)
EP (2) EP2186896B1 (de)
JP (1) JP4886507B2 (de)
AT (1) ATE462003T1 (de)
DE (1) DE602005020121D1 (de)
DK (2) DK1731605T3 (de)
ES (2) ES2556232T3 (de)
PL (1) PL1731605T3 (de)
PT (1) PT1731605E (de)
SI (1) SI1731605T1 (de)
WO (1) WO2005095598A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1103564B1 (de) 1998-07-31 2009-01-07 International Institute of Cancer Immunology, Inc. Krebsantigene, basierend auf dem tumorunterdrückenden genprodukt wt1
US20040097703A1 (en) 2001-03-22 2004-05-20 Haruo Sugiyama Wt1 modified peptide
US8735357B2 (en) * 2001-09-28 2014-05-27 International Institute Of Cancer Immunology, Inc. Method of inducing antigen-specific T cells
ES2538486T3 (es) * 2002-09-12 2015-06-22 International Institute Of Cancer Immunology, Inc. Preparación de péptidos antigénicos contra el cáncer
BRPI0406800B8 (pt) 2003-01-15 2021-05-25 Chugai Seiyaku Kk Chugai Pharmaceutical Co Ltd "dímero de peptídeo, composição farmacêutica contendo o mesmo e seu uso
US10500257B2 (en) * 2003-06-27 2019-12-10 International Institute Of Cancer Immunology, Inc. Method of selecting WT1 vaccine adaptive patient
EP1696027A4 (de) 2003-11-05 2008-05-14 Int Inst Cancer Immunology Inc Aus wt 1 stammendes, hla-dr bindendes antigenpeptid
ES2556232T3 (es) * 2004-03-31 2016-01-14 International Institute Of Cancer Immunology, Inc. Péptidos antigénicos del cáncer derivados de WT1
WO2007047764A2 (en) 2005-10-17 2007-04-26 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
PT1961761E (pt) * 2005-11-30 2010-12-16 Chugai Pharmaceutical Co Ltd Novos compostos peptídicos do tumor de wilms
US8759483B2 (en) 2006-02-22 2014-06-24 International Institute Of Cancer Immunology, Inc. HLA-A* 3303-restricted WT1 peptide and pharmaceutical composition comprising the same
EP2010209B1 (de) 2006-04-10 2016-06-15 Sloan Kettering Institute For Cancer Research Immunogene wt-1-peptide und verfahren zu ihrer verwendung
NZ601175A (en) * 2006-12-28 2012-12-21 Int Inst Cancer Immunology Inc Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
PL2119778T3 (pl) * 2007-02-27 2016-04-29 Int Inst Cancer Immunology Inc Sposób aktywacji pomocniczej komórki T oraz kompozycja do zastosowania w tym sposobie
EP2857508A3 (de) 2007-03-05 2015-04-15 International Institute of Cancer Immunology, Inc. Krebs-Antigen-spezifisches T-Zellen-Rezeptorgen, durch das Gen codiertes Peptid und Verwendung davon
EP2216041A4 (de) * 2007-11-20 2012-10-24 Nec Corp Verfahren zur induktion einer zytotoxischen t-zelle, zytotoxischer t-zell-induktor und pharmazeutische zusammensetzung sowie impfstoff mit dem induktor
KR20110053836A (ko) * 2009-11-16 2011-05-24 삼성에스디아이 주식회사 리튬 폴리머 이차 전지
ES2849187T3 (es) 2010-10-05 2021-08-16 Int Inst Cancer Immunology Inc Método para activar células T auxiliares
CN105968191A (zh) 2011-06-28 2016-09-28 株式会社癌免疫研究所 肽癌抗原-特异性t细胞的受体基因
US9539299B2 (en) * 2011-10-27 2017-01-10 International Institute Of Cancer Immunology, Inc. Combination therapy with WT1 peptide vaccine and temozolomide
EP2776451B1 (de) 2011-11-11 2018-07-18 Fred Hutchinson Cancer Research Center Cyclin a1-gezielte t-zellen-immuntherapie gegen krebs
CN104684577B (zh) 2012-01-13 2018-05-08 纪念斯隆凯特林癌症中心 免疫原性wt-1肽及其使用方法
WO2014042226A1 (ja) 2012-09-12 2014-03-20 株式会社癌免疫研究所 抗原特異的ヘルパーｔ細胞レセプター遺伝子
KR102158225B1 (ko) * 2012-12-17 2020-09-21 오츠카 세이야쿠 가부시키가이샤 헬퍼 t세포의 활성화 방법
PL2945647T3 (pl) 2013-01-15 2021-03-08 Memorial Sloan Kettering Cancer Center Immunogenne peptydy wt-1 i sposoby ich zastosowania
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
CA2840959A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Vaccine composition
JP6512568B2 (ja) 2013-02-05 2019-05-15 日東電工株式会社 経皮投与用ｗｔ１ペプチド癌ワクチン組成物
CA2841014A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Tape preparation of wt1 peptide cancer vaccine for transdermal administration
US20140234377A1 (en) 2013-02-05 2014-08-21 Nitto Denko Corporation Vaccine composition for mucosal administration
JP6440360B2 (ja) 2013-02-05 2018-12-19 日東電工株式会社 経皮投与用ワクチン組成物
EP2762157A1 (de) 2013-02-05 2014-08-06 Nitto Denko Corporation Impfstoffzusammensetzung zur transdermalen oder mukosalen Verabreichung
CA2840988A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Wt1 peptide cancer vaccine composition for mucosal administration
US10071051B2 (en) 2013-02-05 2018-09-11 Nitto Denko Corporation WT1 peptide cancer vaccine composition for transdermal administration
US10023841B2 (en) * 2014-05-23 2018-07-17 Baylor Research Institute Methods and compositions for treating breast cancer with dendritic cell vaccines
EP3177314B1 (de) 2014-08-04 2020-10-07 Fred Hutchinson Cancer Research Center Wt-1-spezifische t-zellen-immuntherapie
KR102588853B1 (ko) 2014-12-25 2023-10-16 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 T 세포 집단의 개변 방법
GB201504502D0 (en) * 2015-03-17 2015-04-29 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
CN106610423A (zh) * 2015-10-26 2017-05-03 复旦大学 评价疫苗疗效的细胞免疫学检测试剂盒及其储存方法
EP3539974B1 (de) 2016-11-09 2023-03-29 Osaka University Verfahren zur modifizierung einer t-zellpopulation
US12259379B2 (en) 2017-06-30 2025-03-25 Osaka University Method for predicting effect of tumor immunotherapy using tumor cytotoxic activity of peripheral blood T cells as index
MX2021010837A (es) 2019-03-11 2021-10-14 Fred Hutchinson Cancer Center Receptores en linfocitos t de la proteina 1 de tumor de wilms (wt1) de alta avidez.
US20220409661A1 (en) 2019-08-20 2022-12-29 Fred Hutchinson Cancer Research Center T-cell immunotherapy specific for wt-1
CN111978375B (zh) * 2020-08-28 2022-10-04 深圳市乐土生物医药有限公司 具有细胞毒性t细胞诱导能力的蛋白质或多肽
CN112250752B (zh) * 2020-12-21 2021-03-26 中生康元生物科技(北京)有限公司 肿瘤新抗原表位肽及其应用
US12404315B2 (en) 2020-12-21 2025-09-02 Allogene Therapeutics, Inc. Protease-activating CD45-gate CAR
KR20230142470A (ko) 2021-01-29 2023-10-11 알로젠 테라퓨틱스 인코포레이티드 동종이계 세포 산물의 T 세포 인식을 완화하기 위한TAP2, NLRC5, β2m, TRAC, RFX5, RFXAP, 및 RFXANK 중 하나 이상의 녹다운 또는 녹아웃
JP2025525779A (ja) 2022-07-29 2025-08-07 アロジーン セラピューティクス，インコーポレイテッド 免疫細胞の認識を低減させるために遺伝子発現が低下した、操作された細胞
WO2025096560A1 (en) 2023-10-30 2025-05-08 Allogene Therapeutics, Inc. Engineered cells

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
EP1103564B1 (de) 1998-07-31 2009-01-07 International Institute of Cancer Immunology, Inc. Krebsantigene, basierend auf dem tumorunterdrückenden genprodukt wt1
IL142216A0 (en) 1998-09-30 2002-03-10 Corixa Corp A polypeptide containing an immunogenic portion of a native wti and pharmaceutical compositions containing the same
US20030235557A1 (en) * 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
GB9823897D0 (en) 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
WO2001025273A2 (en) * 1999-10-04 2001-04-12 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
US20030082194A1 (en) * 2000-02-22 2003-05-01 Alexander Gaiger Compositions and methods for diagnosis and therapy of malignant mesothelioma
US20040097703A1 (en) 2001-03-22 2004-05-20 Haruo Sugiyama Wt1 modified peptide
JPWO2003028758A1 (ja) 2001-09-28 2005-01-13 治夫 杉山 抗原特異的ｔ細胞の誘導方法
US8735357B2 (en) 2001-09-28 2014-05-27 International Institute Of Cancer Immunology, Inc. Method of inducing antigen-specific T cells
EP1536009B1 (de) 2002-06-12 2010-04-28 International Institute of Cancer Immunology, Inc. Hla-a24-restringiertes krebsantigenpeptid
ES2538486T3 (es) 2002-09-12 2015-06-22 International Institute Of Cancer Immunology, Inc. Preparación de péptidos antigénicos contra el cáncer
EP1548028B1 (de) 2002-09-20 2009-09-09 International Institute of Cancer Immunology, Inc. Substituierte wt1-peptide
BRPI0406800B8 (pt) 2003-01-15 2021-05-25 Chugai Seiyaku Kk Chugai Pharmaceutical Co Ltd "dímero de peptídeo, composição farmacêutica contendo o mesmo e seu uso
US10500257B2 (en) 2003-06-27 2019-12-10 International Institute Of Cancer Immunology, Inc. Method of selecting WT1 vaccine adaptive patient
EP1696027A4 (de) 2003-11-05 2008-05-14 Int Inst Cancer Immunology Inc Aus wt 1 stammendes, hla-dr bindendes antigenpeptid
ES2556232T3 (es) 2004-03-31 2016-01-14 International Institute Of Cancer Immunology, Inc. Péptidos antigénicos del cáncer derivados de WT1

Also Published As

Publication number Publication date
DK2186896T3 (en) 2015-12-21
EP1731605A1 (de) 2006-12-13
DE602005020121D1 (de) 2010-05-06
EP1731605B1 (de) 2010-03-24
PT1731605E (pt) 2010-04-14
US7622119B2 (en) 2009-11-24
DK1731605T3 (da) 2010-05-25
US20100062013A1 (en) 2010-03-11
EP1731605A4 (de) 2007-11-07
EP2186896B1 (de) 2015-11-04
SI1731605T1 (sl) 2010-07-30
US20130196427A1 (en) 2013-08-01
PL1731605T3 (pl) 2010-08-31
JP4886507B2 (ja) 2012-02-29
US8388975B2 (en) 2013-03-05
WO2005095598A1 (ja) 2005-10-13
ES2556232T3 (es) 2016-01-14
EP2186896A1 (de) 2010-05-19
ES2341785T3 (es) 2010-06-28
JPWO2005095598A1 (ja) 2008-02-21
HK1144305A1 (en) 2011-02-11
US20080152631A1 (en) 2008-06-26

Similar Documents

Publication Publication Date Title
ATE462003T1 (de) Aus wt1 stammende krebsantigenpeptide
NO20063624L (no) FC region varianter
ATE428727T1 (de) Neue, an den erythropoietinrezeptor bindende peptide
EA200701825A1 (ru) Вакцины против хламидиоза
CY1110980T1 (el) Εμβολιο συνδυασμων πεπτιδιων εναντια στην αλλεργια απο γατες
ATE466084T1 (de) Hla-a24-restringiertes krebsantigenpeptid
DE602008002810D1 (de) Peptide zur desensibilisierung gegenüber allergenen
WO2007062656A3 (en) A nucleotide vaccine
ATE497975T1 (de) Il-21-varianten
ZA200705943B (en) Survivin peptide vaccine
ATE446314T1 (de) Methode zur reinigung von fsh
NO20052149D0 (no) Vaksine.
DK1628989T3 (da) Hidtil ukendte, 14- og 15-leddet ring-forbindelser
ITMI20030107A1 (it) Peptidi derivati da rantes.
DE602005007364D1 (de) Peptidcyclisierung
DK1577320T3 (da) Peptider afledt fra humant BPLP-protein, polynukleotider kodende for nævnte peptider og antistoffer rettet mod nævnte peptider
AP2415A (en) Bacteriocin Inducer peptides.
EP2085474A4 (de) Hla bindendes peptid, dessen vorstufe, dafür codierendes dna-fragment und rekombinanter vektor
ITRM20040489A1 (it) Pentraxina lunga ptx3 deglicosilata o desialidata.
ITMO20030076A0 (it) Valvola di frenatura perfezionata.
WO2009130612A3 (en) Prion epitopes and methods of use thereof
CY1116106T1 (el) Μεθοδος προληψης ή θεραπεια μολυνσης m. tuberculosis
ES1059941Y (es) Rodapie o zocalo calefactor.
ES1058788Y (es) Pieza para la prolongacion bifurcada de postes para la fijacion de alambres de espinos y/o concertinas.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1731605

Country of ref document: EP